CD8A and neoplasm: In particular, venetoclax has demonstrated to i) normalize B, T, and NK-cell count, ii) decrese the percentage of tumor-supportive T-cell subsets, iii) reduce the frequency of PD-1+ CD8+ T cells, and iv) impair NK-cell activation in CLL patients (114).